Bill dossier · California 2025–2026 session · site record current through

SB 1089 — the Preventive Treatment Health Care Act

PRESENTED · AWAITING ACTION

Senator Laura Richardson · presented to the Governor · sign-or-veto deadline

This measure has been presented to the Governor and awaits action. That is the whole of its current status. Presentment starts a constitutional clock; it creates no obligation, imposes no duty on any party, and is not signature, enactment, chaptering or an effective date.

How this status is established

Senate passage 39–0 on 27 May 2026 and Assembly committee movement are reported. Final Assembly passage and the 3 September presentment are recorded here on owner confirmation and have not been verified against the Legislature’s own history entry; that entry attaches to this record when read. The Governor’s office published signing lists on 22, 27 and 31 August 2026 and none on or after 1 September, and this measure appears on none of them. The accompanying analysis states the same limitation in the same terms.

What is established

JURISDICTION

California, 2025–2026 regular session.

INSTRUMENT

Senate bill. The enrolled text is the controlling version.

LIFECYCLE STATE

PRESENTED. Not law, not operative.

SUBJECT

Medi-Cal prescription drug coverage as it concerns GLP-1 receptor agonist pricing, following the termination of Medi-Cal coverage for weight-loss GLP-1 medicines effective .

PRIMARY SOURCE

California Legislative Information — SB 1089

What this page does not claim

A clause-by-clause account of the enrolled text is not given here, because the enrolled text has not been read line by line for this page. In particular no negotiation standard, price benchmark, reporting duty or commencement date is restated. Where the measure’s operative language matters to a decision, read the enrolled text directly rather than any summary — including this one.

  • Presentment is a recorded event. It is not signature, and a signature would in turn not be an effective date — a chapter number and an operative date are separate facts.
  • No party owes anything under this measure today, and nothing in it is in force.
  • The Governor’s office published signing lists on 22, 27 and 31 August 2026 and none on or after 1 September. SB 1089 appears on none of them.

California published extensive utilization and cost reporting on GLP-1 medicines, then ended Medi-Cal coverage of the weight-loss indication on cost grounds. A measure addressing the pricing of the same drug class belongs on the same record as that decision, so the sequence can be read in one place rather than as unconnected events.

Related: the investigation into what the terminated GLP-1 benefit achieved · the California desk · the Governor’s desk · the patient guide to compounded GLP-1 products · generic-drug regulatory capacity

What would change this page

  • Signature, veto, or the lapse of the deadline without signature.
  • A chapter number, and separately an effective and an operative date.
  • A clause-level read of the enrolled text, at which point the operative provisions can be stated rather than described.

Verification date · presentment confirmed by the site owner; the Legislature’s own history entry is attached to this record when read.